Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • MEK1/2 blockade by AZD6244 (AR...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib

MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib

Bibliographic Details
Main Authors: Takahashi, O, Komaki, R, Smith, P, Ryan, A, Jurgensmeier, J, Welsh, J, Jacoby, J, Hosho, K, Korshunova, M, Erez, B, Herbst, R, O'Reilly, MS
Format: Journal article
Published: 2009
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
    by: Gupta, A, et al.
    Published: (2013)
  • AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
    by: Dummer, R, et al.
    Published: (2008)
  • Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
    by: Jin-Hang Gao, et al.
    Published: (2022-03-01)
  • Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
    by: Takahashi, O, et al.
    Published: (2012)
  • Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
    by: Takahashi, O, et al.
    Published: (2012)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs